Approval · Notice of Compliance 2519 · 2001
PAXIL: Notice of Compliance 2519
Issued June 22, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2519
- Date
- June 22, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- Antidepressant, antiobsessional, antipanic agent, social phobia (social anxiety disorder) therapy
Products in this notice
Medicinal ingredients
- PAROXETINE HYDROCHLORIDE 10 MG per TAB
- PAROXETINE HYDROCHLORIDE 20 MG per TAB
- PAROXETINE HYDROCHLORIDE 30 MG per TAB
- PAROXETINE HYDROCHLORIDE 50 MG per TAB